A new impact framework for investors in life sciences bridges financial returns and patient outcomes
- 15 July 2025
- journal article
- editorial
- Published by Springer Nature in Nature Biotechnology
- Vol. 43 (7) , 1041-1046
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast CancerNew England Journal of Medicine, 2024
- Prognostic implications of HER2NEU‐low in metastatic breast cancerCancer Medicine, 2024
- Mortality Associated With Influenza and Respiratory Syncytial Virus in the US, 1999-2018JAMA Network Open, 2022
- Life Expectancy in Duchenne Muscular DystrophyNeurology, 2021
- ADHD, financial distress, and suicide in adulthood: A population studyScience Advances, 2020
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionNew England Journal of Medicine, 2019
- The Current Status of Drug Discovery and Development as Originated in United States Academia: The Influence of Industrial and Academic Collaboration on Drug Discovery and DevelopmentClinical and Translational Science, 2018
- Diagnostic accuracy and prognostic significance of blood fibrosis tests and liver stiffness measurement by FibroScan in non-alcoholic fatty liver diseaseJournal of Hepatology, 2016
- Disability weights for the Global Burden of Disease 2013 studyThe Lancet Global Health, 2015